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INTRODUCTION: 
Nabumetone is a non-steroidal anti-inflammatory drug 
used to treat pain or inflammation caused by arthritis. It 
has poor oral absorption due to poor solubility and low 
dissolution rate.
1
 Therefore a strategy was developed 
pharmaceutically to increase its solubility and dissolution 
by the method of solid dispersions. Solid dispersions is the 
most popularly employed techniques which could improve 
dissolution rate and solubility of poorly water soluble 
drugs by reducing particle size, fractionating to amorphous 
form and improving the wettability. 
2
This transformation 
to amorphous to amorphous form of drug from crystalline 
state attributes to increase in solubility and improves 
bioavailability.
3 
As reported even hydrogen bonding formed between drug 
and carriers is another reason for improved solubility and 
decreased crystallinity of drug in solid dispersions.
4,5
 The 
formulations were prepared by solvent evaporation 
technique and later subjected to various evaluation tests 
like FTIR,XRD and dissolution studies and compared to 
pure drug. Comparison of results with those for pure drug 
powder and physical mixtures of the drug and carrier can 
help to indicate the mechanism by which the carrier 
improves dissolution: via solubilization and wetting effects 
which could be affected by a simple mixture of the 
components, or by formation of a solid dispersion/solution. 
6,7
A well-designed release experiment will show whether 
the solubility of the drug and its dissolution rate has been 
enhanced, and also whether the resulting supersaturated 
solution is stable or tends to precipitate quickly.
8,9,10 
MATERIALS AND METHODS 
Solvent evaporation technique:
11,12
 
Solid dispersions were prepared by solvent evaporation 
method. The carrier PEG  4000 and PEG 6000 are used by 
adding amounts of nabumetone corresponding the  ratio 
1:1;1:2,1:3 and 1:4 was accurately weighed and mixed 
properly. This physical mixture was solubilised in 
common solvent that is in methanol (5ml). The solvent 
was allowed to evaporate in hot air oven at 45C±10c. The 
process of evaporation was opted until the constant weight 
was obtained. The formulation was kept in desiccators for 
24hrs under vacuum. Then, solid dispersion formulation 
was pulverized using a porcelain mortar and pestle. The 
pulverized powder was classified using the sieves (size 
60#) and the powder was used for study.   
Evaluation of prepared solid dispersions: 
Drug content 
The dispersion system equivalent to 10mg of Nabumetone 
Phosphate Buffer was taken in 100ml vol.  Flask and 
dissolved in methanol. The volume was made up to mark 
with buffer and filtered. One ml of filtrate was further 
diluted to 10ml with methanol and absorbance was 
recorded at 271nm. The amount of drug in each dispersion 
system was determined spectrophotometrically. The results 
were shown in table 2   
In Vitro drug release 
In Vitro drug release rate of Nabumetone Phosphate Buffer 
solid dispersion of different samples was determined using 
USP dissolution test apparatus. The dissolution medium 
consisted of 6.8 Phosphate Buffer. Samples of drug, solid 
dispersion equivalent to 100mg  of drug was spread onto 
the surface of 900ml of preheated dissolution medium at 
37  C. Aliquots of 5ml were withdrawn at regular intervals 
of time(5,10,15,20,upto  120min)and the same is replaced 
with fresh dissolution medium each time. The samples 
were measured for absorbance at 271nm. The graph is 
plotted by taking percentage drug release on Y-axis and 
time on X-axis
16
. The results are shown in table 3&4, 
graphs in fig 8&9. 
Fourier transforms Infrared spectroscopy 
FT-IR spectra:
13
 
FT-IR spectra were recorded using an FT-IR 
spectrophotometer (shimadzu).The samples (nabumetone 
PHOSPHATE BUFFER, PEG6000, and solid dispersions) 
were previously ground and mixed thoroughly with 
potassium bromide .Forty scans were obtained at a 
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resolution of 4/cm from 4500/cm.The corresponding 
graphs are shown in fig 1,2,3&4. 
X-ray diffraction:
14,15 
The crystalline state of different samples was evaluated 
with X-ray powder diffraction. Diffraction patterns were 
obtained using an XPERT-PRO diffract meter (PAN 
atypical) with a radius of 240nm. The Cu Kα radiation (K 
α 1.54060A°) was Ni filtered. A system of diverging and 
receiving slits of 1° and 0.1mm respectively was used. The 
pattern was collected with 40kv of tube voltage and 30 mA 
of tube current and scanned over the 2ᵩ  range of 5-60°. 
The corresponding results were shown in fig 5, 6 & 7. 
 
RESULTS: 
Table 1: Formulation of solid dispersions in various ratios: 
Contents F1 F2 F3 F4 F5 F6 F7 F8 
Nabumetone 1 1 1 1 1 1 1 1 
PEG 4000 1 2 3 4 - - - - 
PEG 6000 - - - - 1 2 3 4 
 
Table 2: Drug content 
Formulation Drug content (%) 
F1 9869 
F2 89.78 
F3 88.53 
F4 99.67 
F5 95.56 
F6 92.67 
F7 96.34 
F8 95.23 
 
Table 3: Dissolution studies of formulations with PEG 4000. 
Time F1 F2 F3 F4 Pure Drug 
0 0 0 0 0 0 
10 12.34 14.4 32 44 9.12 
20 20.12 34.2 34 56 15.02 
30 29.34 39.6 48 67 21.21 
40 32.34 44.3 55 79 25.05 
50 40.12 51.2 62 95 32.23 
60 52.23 63 70 98 39.01 
 
Table 4: Dissolution studies of formulations with PEG6000. 
 
Time 
 
F1 
 
F2 
 
F3 
 
F4 
 
Pure Drug 
0 0 0 0 0 0 
 
10 
 
10.56 
 
12.23 
 
15.56 
 
20.12 
 
9.12 
 
20 
 
15.12 
 
20.34 
 
24.34 
 
30.23 
 
15.02 
 
30 
 
26.23 
 
33.23 
 
35.56 
 
41.23 
 
21.21 
 
40 
 
30.34 
 
44.56 
 
46.34 
 
52.34 
 
25.05 
 
50 
 
35.54 
 
49.23 
 
51.23 
 
60.43 
 
32.23 
 
60 
 
40.12 
 
51.43 
 
60.23 
 
74.45 
 
30.01 
Hyma et al                                           Journal of Drug Delivery & Therapeutics; 2013, 3(4), 15-19 17 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Figure 1: FTIR spectra of pure drug 
 
Figure 2: FTIR SPECTRA of PEG 4000 
 
Figure 3: FTIR SPECTRA OF PEG 6000 
 
Figure 4: FTIR Spectra of solid dispersion 
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Figure 5: XRD spectra of nabumetone: 
 
Figure 6: XRD spectra of PEG 4000 
 
Figure 7: XRD spectra of solid dispersion 
 
Figure 8: Dissolution profile of solid dispersions with PEG 
4000 
 
Figure 9: Dissolution profile of solid dispersions with PEG 
6000 
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DISCUSSION: 
FTIR spectra: 
As can be seen, a strong absorption band of c=0 stretching at 
1705 and C=C ring stretching at 1607; 1633; 1484; 150cm-1. 
Occurs int the IR spectrum of Nabumetone. The same 
absorption bands at 1705 & 1605 cm-1 are present in the 
spectra of SOLID DISPERSION of Nabumetone and PEG 
4000.The absence of any shift of carbonyl stretching band and 
alkenes ring stretching band suggested that know chemical 
interaction occurs between Nabumetone and PEG 4000
14
. 
Dissolution Studies 
Invitro Drug Release:-Dissolution profiles of pure drug and 
solid dispersions show that improved dissolution rate is 
proportional with carrier and drug ratio. The influence of PEG 
6000 & PEG 4000 on the dissolution of can be explained by 
the formation of region of high concentration of dissolved 
polymer at the surface of drug crystals in which the drug can 
solublise and subsequently diffuse and dilute in the bulk of 
the solution. At the end of I hour, F1 is 90, F2 is 92, F3 is 95, 
F4 is 101.12, F5 is 100.09, F6 is 99.14, F7 is 99 and F8 is 
98.Based on dissolution studies the optimized formula was 
found to be which released 99 % at the end of 1 hour 
compared to pure drug releasing 39.01 at the end of one hour. 
Therefore f4 was further investigated for further evaluation
17
. 
XRD studies: 
1n XRD study, characteristic peak of drug appeared in 20 
range of 10°-30° indicating that the unprocessed drug was a 
crystalline material. The pure drug exhibit, its characteristic 
diffraction peaks at various diffraction angles indicating the 
presence of crystallinity. The X-Ray diffraction study of solid 
dispersion showed broadening and reduction of major drug 
peaks indicating that mostly an amorphous form existed in 
solid dispersion. These results could explain the observed 
enhancement of solubility and rapid dissolution of drug in 
solid dispersion. 
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